Increasing the Utility of Contrast Agents for MRI
Increasing the Utility of Contrast Agents for MRI
批准号:
7223342
负责人:
MATTHEW J ALLEN
金额:
$7.8万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-12-01 至 2007-11-30
关键词:
AddressAirAreaBiological MonitoringBiologyChelating AgentsChemistryClassClinicalCollaborationsComplexContrast MediaDendrimersDevelopmentDiagnosisDiagnosticDiseaseElectronicsEnhancersFutureGenerationsGoalsImageIonsKnowledgeLanthanoid Series ElementsLeadLigandsMagnetic Resonance ImagingMentorsMentorshipMetalsMethodsNew AgentsNumbersOxygenPhasePolymersPostdoctoral FellowPropertyProtein BiochemistryProteinsPublic HealthPurposeRateResearchResearch PersonnelScientistStagingTechnologyTestingTimeTrainingUniversitiesUrinationWaterWisconsinWorkbasecareerdesignexperienceimprovedin vivomacromoleculenoveloxidationpolymerizationprofessorprogramsresearch studyskills
中文摘要
描述(由申请人提供):
该提案的长期目标是解决造影剂增强磁共振成像(MRI)领域进展的关键障碍。为了克服这些障碍,我的计划是增加镧系造影剂的效用。努力将集中在开发高场MRI造影剂和生理上可行的可活化剂。导师K99阶段:该提案的博士后阶段(目标1)将在L教授的指导下进行。L. Kiessling和R. T.威斯康星大学麦迪逊分校的雷恩斯。K99阶段的目标是使用基于聚合羟基吡啶酮(HOPO)的螯合物开发非常敏感的MRI试剂。在化学和生物学的界面上的这种培训将提供共轭化学,大分子的操作和表征以及新型镧系元素螯合剂的合成方面的专业知识。所获得的知识将证明是非常宝贵的目标2-4的完成和过渡到一个成功的职业生涯作为一个独立的科学家。独立ROO阶段:在独立阶段(目标2-4),目标2和3侧重于开发MRI的生物响应造影剂。目标2涉及开发一类新型的可活化剂,其使用具有真正零背景状态的树枝状聚合物化学。零背景增强将实现浓度非依赖性成像,克服了用于诊断目的的可活化剂的临床使用的主要障碍。目标3中描述的实验集中于HOPO基试剂的内球水配位数的调制。由于水交换速率和内层水分子数量的差异,新试剂将具有优于类似聚(氨基羧酸酯)基试剂的优势。在目标4中,提出了稳定Eu(II)络合物免于氧化的方法。稳定的Eu(II)络合物将在高场强下增强对比度,填充空隙,其中Gd(III)络合物由于长的电子相关时间而不再是可行的对比剂。相关性:该提案有可能通过克服目前的技术限制,提高MRI的诊断能力,从而大大改善公众健康。拟议中的研究可能会导致在治疗通常更有效的最早阶段诊断疾病的能力。
英文摘要
DESCRIPTION (provided by applicant):
The long-term goals of this proposal are to address critical barriers to progress in the field of contrast agent-enhanced magnetic resonance imaging (MRI). My plan to overcome these barriers is to increase the utility of lanthanide-based contrast agents. Efforts will be focused on the development of contrast agents for high field MRI and activatable agents that are physiologically viable. Mentored K99 Phase: The postdoctoral phase (aim 1) of the proposal will be carried out under the mentorship of Professors L. L. Kiessling and R. T. Raines at the University of Wisconsin-Madison. The K99 phase goal is to develop exquisitely sensitive MRI agents using polymeric hydroxypyridonate (HOPO)-based chelates. This training at the interface of chemistry and biology will provide expertise in conjugation chemistries, manipulation and characterization of macromolecules, and the synthesis of novel lanthanide chelators. The acquired knowledge will prove invaluable for completion of aims 2-4 and transition into a successful career as an independent scientist. Independent ROO Phase: In the independent phase (aims 2-4), aims 2 and 3 focus on the development of biologically responsive contrast agents for MRI. Aim 2 involves the development of a novel class of activatable agents using dendrimer chemistry that have a true zero-background state. Zero background enhancement would enable concentration-independent imaging, overcoming a major barrier to the clinical use of activatable agents for diagnostic purposes. The experiments described in aim 3 focus on modulation of the innersphere water coordination number of HOPO-based agents. The new agents will have advantages over similar poly(aminocarboxylate)-based agents due to differences in water exchange rate and number of innersphere water molecules. In aim 4, methods to stabilize Eu(ll) complexes from oxidation are proposed. Stable Eu(ll) complexes will enhance contrast at high field strengths filling the void where Gd(lll) complexes cease to be viable contrast agents because of long electronic correlation times. Relevance: This proposal has the potential to greatly improve public health through advancement of the diagnostic capabilities of MRI by overcoming current technological limitations. The proposed research may lead to the ability to diagnose diseases at the earliest stages where treatments are often more effective.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
MARC at Wayne State University
-
批准号:10408118
-
项目类别:
-
资助金额:$39.67万
-
财政年份:2021
-
负责人:MATTHEW J ALLEN
-
依托单位:
MARC at Wayne State University
-
批准号:10620738
-
项目类别:
-
资助金额:$40.13万
-
财政年份:2021
-
负责人:MATTHEW J ALLEN
-
依托单位:
Library Synthesis and Screening of Eu(II)-Based Contrast Agents
-
批准号:10093042
-
项目类别:
-
资助金额:$31.56万
-
财政年份:2019
-
负责人:MATTHEW J ALLEN
-
依托单位:
Library Synthesis and Screening of Eu(II)-Based Contrast Agents
-
批准号:10377906
-
项目类别:
-
资助金额:$32.01万
-
财政年份:2019
-
负责人:MATTHEW J ALLEN
-
依托单位:
Library Synthesis and Screening of Eu(II)-Based Contrast Agents
-
批准号:10330634
-
项目类别:
-
资助金额:$10.0万
-
财政年份:2019
-
负责人:MATTHEW J ALLEN
-
依托单位:
Intratumoral imaging of hypoxia using 1H- and 19F-MRI with redox-responsive Eu-based contrast agents
-
批准号:10239104
-
项目类别:
-
资助金额:$65.61万
-
财政年份:2018
-
负责人:MATTHEW J ALLEN
-
依托单位:
Study of Advanced Eu(II)-Based Contrast Agents for Ultra-High Field Magnetic Reso
-
批准号:8628271
-
项目类别:
-
资助金额:$32.54万
-
财政年份:2014
-
负责人:MATTHEW J ALLEN
-
依托单位:
Study of Advanced Eu(II)-Based Contrast Agents for Ultra-High Field Magnetic Reso
-
批准号:9059260
-
项目类别:
-
资助金额:$5.12万
-
财政年份:2014
-
负责人:MATTHEW J ALLEN
-
依托单位:
Study of Advanced Eu(II)-Based Contrast Agents for Ultra-High Field Magnetic Reso
-
批准号:9043062
-
项目类别:
-
资助金额:$33.6万
-
财政年份:2014
-
负责人:MATTHEW J ALLEN
-
依托单位:
Study of Advanced Eu(II)-Based Contrast Agents for Ultra-High Field Magnetic Reso
-
批准号:8806558
-
项目类别:
-
资助金额:$31.76万
-
财政年份:2014
-
负责人:MATTHEW J ALLEN
-
依托单位:
Increasing the Utility of Contrast Agents for MRI
-
批准号:7753605
-
项目类别:
-
资助金额:$24.75万
-
财政年份:2008
-
负责人:MATTHEW J ALLEN
-
依托单位:
Increasing the Utility of Contrast Agents for MRI
-
批准号:7515492
-
项目类别:
-
资助金额:$24.9万
-
财政年份:2008
-
负责人:MATTHEW J ALLEN
-
依托单位:
Increasing the Utility of Contrast Agents for MRI
-
批准号:7541763
-
项目类别:
-
资助金额:$25.0万
-
财政年份:2008
-
负责人:MATTHEW J ALLEN
-
依托单位:
Multivalent Antibody Ligands for Clearance of Pathogens
-
批准号:6886737
-
项目类别:
-
资助金额:$4.4万
-
财政年份:2004
-
负责人:MATTHEW J ALLEN
-
依托单位:
Multivalent Antibody Ligands for Clearance of Pathogens
-
批准号:6793362
-
项目类别:
-
资助金额:$4.11万
-
财政年份:2004
-
负责人:MATTHEW J ALLEN
-
依托单位:
Multivalent Antibody Ligands for Clearance of Pathogens
-
批准号:7032333
-
项目类别:
-
资助金额:$3.49万
-
财政年份:2004
-
负责人:MATTHEW J ALLEN
-
依托单位:
国内基金
海外基金
湍流和化学交互作用对H2-Air-H2O微混燃烧中NO生成的影响研究
-
批准号:51976048
-
项目类别:面上项目
-
资助金额:61.0万元
-
批准年份:2019
-
负责人:邱朋华
-
依托单位: